Tscan Therapeutics Inc (TCRX) stock news · rev $10.3M
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
This TCRX news page leads with what Tscan Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for TCRX yet. We will not pad this page with generic market recap.
Latest reported TCRX revenue for 2025-12-31 was $10.3M. Net income was -$129.8M. Revenue was up 266.7% from 2024-12-31 to 2025-12-31. TCRX currently screens at market cap $62.1M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the TCRX stock page; for the tape open the quote page.
TCRX stock news FAQ
What are TCRX's latest revenue and net income?
Latest cached Tscan Therapeutics Inc (TCRX) revenue for Dec 31, 2025 was $10.3M. Net income was -$129.8M. Statements: https://lician.com/financials/tcrx
How did TCRX revenue change from the prior cached period?
Cached Tscan Therapeutics Inc (TCRX) revenue was up 266.7% from $2.8M (Dec 31, 2024) to $10.3M (Dec 31, 2025). Statements: https://lician.com/financials/tcrx
What is TCRX's market cap?
Tscan Therapeutics Inc (TCRX) market cap is $62.1M on the latest cached fundamentals snapshot.
What kind of company is TCRX?
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
Where is TCRX stock news listed?
Cached stock news for Tscan Therapeutics Inc (TCRX) is listed at https://lician.com/news/tcrx. Filings: https://lician.com/sec/tcrx
Not investment advice.